ClinicalTrials.gg
Active, not recruitingNCT06799559Updated Oct 14, 2026

Study on the Efficacy and Safety of QLM1016 in Schizophrenia

A Phase 3 interventional study of 3-6mg QLM1016 and 10-20 mg Aripiprazole oral solution film in Schizophrenia, sponsored by Qilu Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 14, 2026Now Active, not recruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
29th of 216
402 · median 100
Started
2025
with 15 others
Phase 3
35 of 252
3 open now
Primary completion
2026-10
later than 24 of 67 live
Registered
198th of 252
by date

Among the 252 studies in Schizophrenia with a site in China, this one is the 29th largest by planned enrollment of the 216 interventional ones that give a count, is one of 16 that started in 2025, is one of 35 in phase 3, reaches primary completion later than 24 of the 67 other live ones, and was the 198th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects, ages 18-65 inclusive, with a clinical diagnosis of schizophrenia
  • PANSS total score ≥ 70 and ≤ 120,Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms: delusions, hallucinatory behavior, conceptual disorganization, and unusual thought content
  • CGI-S score ≥ 4

Exclusion criteria

Exclusion Criteria:

  • Currently, meet diagnostic criteria for other psychiatric disorders ( for example schizoaffective disorder, schizophreniform disorder, bipolar I and II disorder; pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders;
  • known or suspected borderline or antisocial personality disorder or other psychiatric disorders of sufficient severity to interfere with participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
402 participants (estimated)

Study arms

  • Experimental
    QLM1016

    Drug: 3-6mg QLM1016

  • Active comparator
    Aripiprazole oral solution film

    Drug: 10-20 mg Aripiprazole oral solution film

Interventions

  • Drug3-6mg QLM1016

    3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks

  • Drug10-20 mg Aripiprazole oral solution film

    10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.

06

What researchers measure

Primary outcomes

  1. change from baseline to week 6 in the Positive and Negative Syndrome Scale (PANSS) total score

    Time frame: Time Frame: 6 weeks

07

Study locations

1 site
  • No. 8888 Lvyou Road
    Jinan, Shandong 250000, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start May 2025 → Oct 2025 and primary completion Jul 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Oct 2, 2025was May 2025
Primary completionEst.
Oct 23, 2026was Jul 2026
CompletionEst.
Dec 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 14, 2026
Sites
1 site added — first site in China
Show site
  • No. 8888 Lvyou Road · Jinan, China
Oct 14, 2026
Start date
May 2025→Oct 2, 2025 (actual)
Oct 14, 2026
Primary completion
Jul 2026→Oct 23, 2026
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in China
    Show site
    • No. 8888 Lvyou Road · Jinan, China
    Start date May 2025→Oct 2, 2025 (now actual)
    Primary completion Jul 2026→Oct 23, 2026
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06799559
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Oct 2, 2025
Primary completion
Oct 23, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion